R. Mesía Nin

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Athanassios Argiris, Kevin J. Harrington, Makoto Tahara et al. · Annals of Oncology · 2021 · 31 citations

Medicine, Oncology, Pharmacotherapy +13

Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population

David Virós Porcuna, Carlos Pollán Guisasola, Constanza Viña Soria et al. · Clinical & Translational Oncology · 2019 · 23 citations

Medicine, Oncology, Surgery +13

Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)

Ezra E.W. Cohen, David S. Hong, T. Wise Draper et al. · Annals of Oncology · 2017 · 20 citations · Full text

Medicine, Oncology, Pharmacology +11

SEOM clinical guidelines for the treatment of head and neck cancer

R. Mesía Nin, Miguel Pastor Borgoñón, Juan Jesús Cruz et al. · Clinical & Translational Oncology · 2010 · 15 citations

Medicine, Oncology, Surgery +14